Switzerland-based Anergis SA, the clinical-stage developer of allergy immunotherapies, has appointed Klaus Schollmeier as chairman of its board of directors. He replaces Jacques-François Martin whose term ended in 2016. A veteran manager, Dr Schollmeier was chief executive of SuppreMol GmbH, which was sold to Baxter in 2015. Before that, he served as CEO of Santhera Pharmaceuticals in Switzerland.
Anergis SA announced the appointment on 24 January 2017.
Copyright 2017 Evernow Publishing Ltd